Risk of Surgical Complications Up for Overlapping Hip Surgery

Share this content:
Risk of Surgical Complications Up for Overlapping Hip Surgery
Risk of Surgical Complications Up for Overlapping Hip Surgery

MONDAY, Dec. 4, 2017 (HealthDay News) -- For patients undergoing surgery for hip fracture or total hip arthroplasty (THA), overlapping surgery is associated with increased risk of surgical complications, according to a study published online Dec. 4 in JAMA Internal Medicine.

Bheeshma Ravi, M.D., Ph.D., from the University of Toronto, and colleagues examined whether overlapping surgery is associated with greater risk of complications in a retrospective population-based cohort study for 2009 to 2014. Participants from two large cohorts were included and followed up for one year. The hip fracture cohort included all persons aged older than 60 years who underwent surgery for a hip fracture, while the THA cohort included all primary elective THA recipients for arthritis. Overlapping and nonoverlapping hip fractures were matched for patient age and sex, surgical procedure (for the hip fracture cohort), primary surgeon, and hospital.

The researchers identified 38,008 hip fracture surgeries, of which 2.5 percent were overlapping. There were 52,869 THAs, 3.0 percent of which were overlapping. Overlapping hip fracture procedures had an increased risk of complications after matching, as did overlapping THA procedures (hazard ratios, 1.85 and 1.79, respectively). Increasing duration of operative overlap correlated with increasing risk for complications among overlapping hip fracture operations (adjusted odds ratio, 1.07 per 10-minute increase in overlap).

"These findings support the notion that overlapping provision of surgery should be part of the informed consent process," the authors write.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »